Wire · regulatory
Martin Shkreli violated lifetime pharma industry ban, FTC and states say
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 October 2026 · Fusion42 review
Martin Shkreli violated a lifetime ban from the pharmaceutical industry by trading stocks and discussing pharma companies, prompting the FTC and seven states to seek contempt charges and a fine based on his profits since early 2022.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 8 sources have reported it between 13 Oct 2026 and 14 Oct 2026.
◆ ◆ The Wire takeaway
Pharma founders face stricter scrutiny as regulators back enforcement of lifetime bans with contempt and fines. You must reassess compliance risks around market conduct and public commentary to avoid similar penalties.
◆ Coverage
8 sources · first reported 13 Oct 2026 · latest 14 Oct 2026
◆ Topics